You are here: Home / Public / News

ENATRANS News

6th Round of applications to the NanomedTAB is open
The Nanomedicine Translation Advisory Board (nanomedTAB) offers since 2015 a free-of-charge mentoring program to assess, advise and accelerate promising nanomedicine projects to the market, based on a team of top skills industry experts with diverse and complementary experience. The objective? Help all projects and teams to get to clinical and commercial application faster and more reliably.
Nanomedicine Translation around the globe - How to proper address regulatory processes for nanomedicines in different countries
Nanomedicine Award 2017: applications are now open!
The European Technology Platform for Nanomedicine (ETPN) and the EU-funded project ENATRANS, announce the launching of the 3rd edition of the Nanomedicine Award, which aims to promote and reward two excellent innovative nanomedicine-based solutions that could bring significant benefits to patients, answering thereby unmet medical needs. The winners in both categories will be announced and rewarded during the BIO-Europe conference in Berlin in November 2017. Apply Now!
First European Nanomed "Who's who"
The first "Who's who" dedicated to European SMEs in nanomedicine is about to go live!
EMA PRIME: an opportunity for the translation of Nanomedicine?
The European Medicines Agency (EMA) launched PRIME (PRIority MEdicines), a new scheme to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier.
Interview of Dr. Klaus-Michael Weltring - Nanotechnology: a key to the future of medicine Interview
The COMPAMED Magazine interviewed the ENATRANS Partner Klaus-Michael Weltring to discuss about expectations, achievements, gaps and barriers for future medical products based on naotechnologies.
EU-NCL- First call for characterisation of injectable nanomedicines addressing cancer
The recently established European Nanomedicine Characterisation Laboratory (EU-NCL) aims at providing critical infrastructure and characterisation services that are needed to analyse physical and chemical attributes, in vitro biological properties, and in vivo characteristics of emerging nanomedicines ready for translation and clinical trials.
Filed under: